Slide 1: First Quarter 2022 Operating & Financial Results Conference Call / Webinar
First Quarter 2022 Operating & Financial Results Conference Call / Webinar May 3rd, 2022 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents, Speakers, Host
Contents Speakers Host 01 Introduction Panna Sharma Chief Executive Officer, President and Director 02 Q1 2022 Highlights 03 Scientific Progress Dr. Kishor Bhatia Chief Scientific Officer 04 Financial Highlights Nicole Leber Investor Relations David Margrave 05 Q&A Chief Financial Officer
Slide 4: Lantern Pharma
Lantern Pharma Leveraging A.I. to reduce oncology drug development costs and improve the likelihood of success Abundance of data Proprietary A.I. platform RADR® Accelerated timeline and reduced cost First Quarter 2022 Earnings 3
Slide 5: First Quarter 2022 Highlights
First Quarter 2022 Highlights Harmonic™ Trial Australia Operation • Submitted IND amendment including a finalized • Actively conducting multiple studies in Australia clinical study protocol to the FDA in mid-April for under Lantern Australian subsidiary Phase 2 trial • Takes advantage of R&D tax inc
Slide 6: Harmonic Clinical Trial – Phase 2 Trial for LP-300
Harmonic™ Clinical Trial – Phase 2 Trial for LP-300 2 Year Survival Overall Survival 125% median survival increase 91% median survival increase Total expected patients Total expected sites 90 Patients 15-20 Sites Estimated first patient enrollment Summer 2022 • Harmonic™ clinical trial is a Phase 2,
Slide 7: LP-184 IND enabling studies
LP-184 IND enabling studies Study Type Method Results At NOAEL in dogs LP-184 PK parameters measured on dosing days 1 and 15 showed NOAEL ○ t1/2 = 40-50 min Dog non-GLP tox study 0.3mg/kg for repeat weekly dosing ○ Cmax = 800 nM (days 1, 8 and 15) ○ Tmax = 5 min Completed ○ At 0.3mg/kg some hematoto
Slide 8: LP-184 in brain metastases: unmet clinical need
In vitro efficacy of our drug candidate LP-184 in brain metastases (mets.), LP-184 is 6X more potent than early generation EGFR TKIs in brain metastasis models from primary lung cancer 800 5000 4283 Unmet Clinical Need 4051 LP-184 IC50 (nM) 611 4000 LP-184 IC50 (nM) 600 in Brain Metastases 3209 418
Slide 9: Lantern established an Australian subsidiary
Lantern established an Australian subsidiary Established Australia subsidiary to take advantage of Australia’s Research & Development Tax Incentive Lantern Pharma Australia Pty Ltd, a Lantern subsidiary, was established in Australia in September 2021 Subsidiary will allow: o Lantern to take advantag
Slide 10: RADR Surpassed 20 Billion Datapoints
RADR® Surpassed 20 Billion Datapoints Future Goals For A.I. Platform 1. Focus on automation of data acquisition 2. Improve data user interface to other analytical tools and containers 3. Improve tagging of metadata 4. Enter into additional value-based biopharma collaborations Our goal is to expand R
Slide 11: LP-300 Mechanism of action
LP-300 Mechanism of action LP-300 • LP-300 in previous clinical trials has been well tolerated in around 1,000 people. • In a subset of Never Smoker patients from a larger NSCLC trial, patients who received LP-300 with chemotherapy showed increased overall and 2-year patient LP-300 molecule survival
Slide 12: LP-184 shows exquisite sensitivity in NERD as well as HRD cancers
LP-184 shows exquisite sensitivity in NERD as well as HRD cancers LP-184 in NERD cancers LP-184 in HRD cancers • NERD tumors are nucleotide excision repair deficient tumors whose phenotype is a result of mutations in genes • HRD are Homologus recombination deficient tumors and responsible for excisi
Slide 13: Financial Update Q1 2022
Financial Update Q1 2022 Summary Results of Operations Balance Sheet Highlights & Summary Three Months Ended March 31, (unaudited) (unaudited) 2022 2021 3/31/2022 12/31/2021 Operating expenses: Cash and Marketable Securities $ 65,216,479 $ 70,725,447 Prepaid Expenses General and administrative 1,406
Slide 14: LTRN Share Information
LTRN Share Information March 31, 2022 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 10,830,947 Warrants 177,998 Options (Employees, Management and Directors) 890,826 Fully Diluted Shares Outstanding 11,899,771 To t a l P a i d Shares Average Date including Repurchased Price Commission FY 2021
Slide 15: New Director Nominee Maria L. Maccecchini, Ph.D.
Maria Maccecchini, Ph.D. was nominated for election to Lantern’s Board of Directors New Director Nominee Maria L. Maccecchini, Ph.D. Founder, President, Chief Executive Officer, and director of Annovis Bio (NYSE: ANVS) Dr. Maccecchini will be presented alongside a slate of five existing Directors at
Slide 16: Upcoming Events
Upcoming Events MAY JUNE 9th Drug Discovery Strategic Summit LD Micro Invitational 9 Speaker: Kishor Bhatia 7 Speaker: Panna Sharma Strategic Investment Conference JULY 13 Speaker: Panna Sharma World Orphan Drug 11 Congress USA 2022 Speaker: Panna Sharma MedVentures Conference 2022 18 Speaker: Panna
Slide 17: Key Corporate Objectives and Milestones
Key Corporate Objectives and Milestones ● 2022 Objectives and Milestones Launch of The Harmonic™ Trial - Ph. 2 clinical trial for LP-300 in NSCLC ● Advance LP-100 clinical development ● Launch Ph. 1 clinical trial for LP-184 in genomically defined solid tumors ● Design Ph. 2 clinical trial for LP-18
Slide 18: Nasdaq: LTRN
www.lanternpharma.com @LanternPharma Nasdaq: LTRN IR Contact: IR@lanternpharma.com 1-972-277-1136